linjc16/ctgov huggingface dataset:
Evaluation of Satisfaction in Patients Undergoing Non Surgical Lifting by Means of Coned Wires.

Study Overview
=================
Brief Summary
-----------------
An email questionnaire about subjective satisfaction and discomfort has been sent to 243 patients undergoing non-surgical facial and cervical lift 1 week, 1 month, 6 months and 1 year after treatment.

Detailed Description
-----------------
243 patients underwent non-surgical coned wires (silhouette soft) facial and cervical lift between October 2013 and November 2014. The procedures has been executed in our aesthetic clinics in Milan, Bologna, Turin, Genoa, Rome, Asti, San Remo and Palermo. Among the 243 patients, 217 were females and 26 males, with age ranging from 19 to 76 years. 103 patients underwent only facial lift, of which 12 only in the frontal area, 61 only on cheek and malar area, and 30 on both the areas. 39 patients underwent only cervical lift, of those 14 by means of appliance of 1 or 2 wires, 25 by means of appliance of more than 2 wires. 101 patients underwent both facial and cervical non surgical lift. We sent to every patient a email questionnaire1 week, 1 month, 6 months and 1 year after treatment. In the questionnaire, patients has been asked to enter a value between 1 and 5 about subjective satisfaction regarding the aesthetic improvement (ranging from 1, poor, to 5, excellent), and discomfort related to treatment (ranging from 1, no perceived discomfort, to 5, impossibility to execute working and social activities). The data has been analyzed and related to other factors such as: number of wires applied on each patient other aesthetic or regenerative medicine treatments executed on the same patient on the same year total expenditure related to aesthetic treatments in the same year

Official Title
-----------------
Evaluation of Aesthetic Satisfaction in Patients Undergoing Non Surgical Face and Neck Lift by Means of Coned Wires.

Conditions
-----------------
Pain, Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing facial and cervical non surgical lift by means of resorbable coned wires Exclusion Criteria: Patients with asymmetry

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 76 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective satisfaction questionnaire |  | up to one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discomfort related to treatment questionnaire |  | one week, one month, 6 months, one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coned wires, wire lift,, patient, discomfort
Livet Skal Leves (A Life to Live)

Study Overview
=================
Brief Summary
-----------------
The overall objective of this project is to optimize the use of diagnostic methods and follow-up programs in infants with congenital heart defects (CHDs) in order to reduce death and complications

Detailed Description
-----------------
The project is designed as retrospective cohort study based on nationwide registry data of children born 2004-16. The project group has extensive experience of similar research, and includes representatives from different fields and levels of health care. The results will provide a solid fundament for improvement of today's clinical practice, including development of knowledge-based routines in neonatal medicine and planning of health care services. Implementation is given particular attention, and will be managed in an interdisciplinary setting. The project will be of major relevance for the patients and their families as well as medical professionals at all levels of health care.

Official Title
-----------------
Heart Defects in Infants- Detection, Rescue and Care

Conditions
-----------------
Heart Defects, Congenital

Intervention / Treatment
-----------------
* Procedure: Heart surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fetuses with severe CHDs who were identified by antenatal ultrasound screening, and where the pregnancy was terminated Children with severe congenital heart defects born in Norway 2004-18 Exclusion Criteria: Lack of parental consent

Ages Eligible for Study
-----------------
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Heart surgery|All invasive procedures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | All deaths including prenatal termination of pregnancy | 0-2 years |
Pontos-Central Venous Pressure and Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Recent studies indicated the central venous pressure (CVP) as a prognostic marker. Therefore, we retrospectively analyzed the CVP on admission to the intensive care unit (ICU) in cardiac surgery patients regarding its prognostic value for morbidity and mortality.

Official Title
-----------------
High Central Venous Pressure After Cardiac Surgery is Associated With Increased Morbidity and Mortality

Conditions
-----------------
Central Venous Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In-patients of the Charité Universitätsmedizin Berlin at least 18 years old female or male sex cardiosurgical intervention (OPS 5.35 and 5.36) between 01/06 and 12/13. post-operative monitoring of anesthesiological intensive care unit Exclusion Criteria: previous cardiosurgical interventions during the same hospital stay. incomplete documentation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | In-Hospital mortality | an average of 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central venous pressure | central venous pressure on intensive care unit | intensive care unit stay, an average of 5 days | 
| Hospital stay | Length of hospital stay | an average of 13 days | 
| ICU stay | Intensive care unit length of stay | an average of 5 days | 
| ICU readmission | Amount of hospital readmissions | an average of 30 days | 
| Renal insufficiency - 1 | Incidence of renal insufficiency | intensive care unit stay, an average of 5 days | 
| Renal insufficiency - 2 | dialysis duration | intensive care unit stay, an average of 5 days | 
| Renal insufficiency - 3 | Urine production | intensive care unit stay, an average of 5 days | 
| Stroke | incidence of strokes | hospital length of stay, an average of 13 days | 
| mortality rate-1 | mortality rate after 90 days | 90 days | 
| mortality rate-2 | mortality rate after 180 days | 180 days | 
| mortality rate-3 | mortality rate after 3 years | 3 years | 
| mortality rate-4 | mortality rate after 1 year | 1 year | 
| mortality rate-5 | mortality rate after 5 years | 5 years |
Ranibizumab Treatment for Age-Related Macular Degeneretion

Study Overview
=================
Brief Summary
-----------------
To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.

Official Title
-----------------
The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients

Conditions
-----------------
Visual Disorder Due to Age-related Macula Degeneration

Intervention / Treatment
-----------------
* Drug: Intravitreal Lucentis 0.5mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD Subjects of either gender age 50 years or older Visual acuity better than 0.05 decimal( 20/400 Snellen) Signed informed consent form Exclusion Criteria: Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors The pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ranibizumab<br> | Drug: Intravitreal Lucentis 0.5mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baseline change of visual acuity and QOL after ranibizumab treatment | Analyze the correlation between visual acuity improvement and QOL assessment using VFQ-25 and Patient Satisfaction Questionnaire before and after initial ranibizumab treatment for AMD patients. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the correlation between the changes of visual acuity and QOL measurement during one year follow-up observations |  | 1year |
Comfort and Cleaning Evaluation of Multipurpose Solutions in Contact Lens Patients

Study Overview
=================
Brief Summary
-----------------
To compare patient comfort and overall lens cleanliness with consecutive use of two multipurpose lens solutions.

Conditions
-----------------
Patient Comfort, Lens Cleanliness

Intervention / Treatment
-----------------
* Drug: new MPS, opti-free express no rub MPS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 yrs or older Males or females Any race or ethnic background CL patients using Opti-Free Express no-rub MPS currently Patients using Focus night and day Lenses Exclusion Criteria: Corneal refractive surgery within 6 months of this study. Corneal ectasia. Current use of Restasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: new MPS, opti-free express no rub MPS|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of Post-craniotomy Headache in Siriraj Hospital

Study Overview
=================
Brief Summary
-----------------
Headache after major craniotomy may be a problem in taking care of the patients. The investigators want to identify the incidence of headache after major craniotomy and also the risk factors.

Official Title
-----------------
Prevalence of Post-craniotomy Headache in Siriraj Hospital

Conditions
-----------------
Adult Brain Tumor, Headache

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient undergoing major craniotomy Exclusion Criteria: emergency surgery or traumatic patients may need postoperative ventilatory support more than 2 days cannot communicate psychiatric patients chronic use of benzodiazepine or drug abuse cannot follow the treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Craniotomy<br>Patient undergoing major craniotomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of headache after major craniotomy | By asking the patients about the symptoms | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factors of headache after major craniotomy such as sex, education | by collecting the patients data | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
craniotomy, headache, postoperative
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Study Overview
=================
Brief Summary
-----------------
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: REGN1400
* Drug: Erlotinib
* Drug: Cetuximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria include, but are not limited to, the following: Confirmed diagnosis of certain unresectable or metastatic cancers Adequate Eastern Cooperative Oncology Group (ECOG) performance status Adequate hepatic, renal and bone marrow function Resolution of toxicity from prior therapy to grade less than/ = to 1 Exclusion Criteria include, but are not limited to, the following: Active brain metastases Thromboembolic events < 6 months prior to study Patients with a recent history (within 5 years) of another malignancy. Investigational or any antitumor treatment with a maximum of 4 half-lives or administered 30 days prior to the initial administration of REGN1400 Patients who are pregnant or nursing Prior treatment with ErbB3 inhibitors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1<br>Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab | Drug: REGN1400<br> <br> Drug: Erlotinib<br> <br> Drug: Cetuximab<br> <br> |
| Experimental: Cohort 2<br>Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab | Drug: REGN1400<br> <br> Drug: Erlotinib<br> <br> Drug: Cetuximab<br> <br> |
| Experimental: Cohort 3<br>Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab | Drug: REGN1400<br> <br> Drug: Erlotinib<br> <br> Drug: Cetuximab<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of the study is to characterize the safety profile of REGN1400 alone and in combination with erlotinib or cetuximab | Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4. | Day 1 - Day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recommended Phase 2 Dose (RP2D) | Determine a recommended phase 2 dose (RP2D) of REGN1400 in combination with erlotinib or cetuximab | Day 1 to Day 28 |
Prospective Study of Liver Mobilization With the Levita Magnetic Surgical System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effectiveness of the Levita Magnetic Surgical System in patients undergoing bariatric procedures

Detailed Description
-----------------
Prospective, multicenter, single-arm, open label study designed to assess the safety and effectiveness of the Levita Magnetic Surgical System in bariatric procedures.

Official Title
-----------------
Prospective Study of Liver Mobilization With the Levita Magnetic Surgical System

Conditions
-----------------
Bariatric Surgery Candidate

Intervention / Treatment
-----------------
* Device: Levita Magnetic Surgical System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years of age scheduled to undergo bariatric procedure Exclusion Criteria: Am Soc Anesthesiology score of III or IV significant comorbidities subjects contraindicated for use of magnetic system clinical history of impaired coagulation hepatic abnormality or anatomical abnormality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Levita Magnetic Surgical System | Device: Levita Magnetic Surgical System<br>* use of surgical tool<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and types of tools required to mobilize the liver during procedure | The ability to mobilize the liver will be evaluated by recording the number and types of tools used to mobilize the liver during a bariatric procedure. If another tool besides the Magnetic Surgical System (MSS) is required to move the liver then the use of the MSS has not been successful. | During planned bariatric procedure. (approximately 2 hours on a single day.) | 
| Incidence of device related adverse events (safety) | All adverse events will be recorded and allocated as to relatedness to device, procedure or other. | Through 30 days post bariatric procedure |
The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan

Study Overview
=================
Brief Summary
-----------------
This study is the first hospital-based, cross-sectional study to discuss the prevalence of obesity among 710 inpatients with schizophrenia.

Official Title
-----------------
The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan

Conditions
-----------------
Schizophrenia, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis as ICD 295 Living in rehabilitation ward during 2010/03/22 2010/04/02 Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Inpatient schizophrenia or schizoaffective disorder<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index (BMI) |  | cross-sectional study, check one time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| waist circumference |  | cross-sectional study, check for one time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, inpatient, obesity, prevalence
Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics

Study Overview
=================
Brief Summary
-----------------
Diabetes mellitus is becoming a global epidemic. There is a need to devise a non invasive method for detection of diabetes and its related complication. Tear proteins are easy to collect causing no harm to a patient and different studies indicate that tear proteins of diabetic patients are significantly different from non diabetic population. This difference in the composition of tear proteins become more pronounced with advancement of diabetic retinopathy.

Detailed Description
-----------------
Diabetes mellitus causes a significant alteration in tear proteins. If we analyze tear proteins by means of electrophoresis, HPLC, and mass spectroscopy. We can find different type of tear proteins in different grades of diabetic retinopathy these biomarkers can help in mass screening , diagnosis and management of diabetic population.

Official Title
-----------------
Tear Proteins and Diabetic Retinopathy

Conditions
-----------------
Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetic patients with type 2 diabetes age above 30 willing to participate Exclusion Criteria: ocular surface disorders. collagen vascular diseases Limbal hyperemia previous ocular surgery creatinine level above 1.0 liver diseases

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non diabetic<br>Normal age and sex matched population | |
| Grade 1<br>Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy | |
| Grade 2<br>Moderate non proliferative diabetic retinopathy | |
| Grade 3<br>Severe non proliferative diabetic retinopathy | |
| Grade 4<br>Proliferative diabetic retinopathy and advanced diabetic eye disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tear proteins, diabetic retinopathy, HPLC, Mass spectroscopy